Skip directly to page options Skip directly to A-Z link
Volume 27, Number 11—November 2021
Research

Hepatitis A Virus Incidence Rates and Biomarker Dynamics for Plasma Donors, United States

Stephanie Schoch, Martin Wälti, Mathias Schemmerer, Rick Alexander, Björn Keiner, Carol Kralicek, Keith Bycholski, Kelley Hyatt, Jon Knowles, Denis KlochkovComments to Author , Toby Simon, Jürgen J. Wenzel, Nathan J. Roth, and Eleonora Widmer
Author affiliations: CSL Behring AG, Bern, Switzerland (S. Schoch, M. Wälti, D. Klochkov, N.J. Roth, E. Widmer); University Medical Center Regensburg, Regensburg, Germany (M. Schemmerer, J.J. Wenzel); CSL Plasma, Knoxville, Tennessee, USA (R. Alexander); CSL Behring GmbH, Marburg, Germany (B. Keiner); CSL Plasma, Boca Raton, Florida, USA (K. Bycholski, K. Hyatt, J. Knowles, T. Simon); CSL Plasma, Dallas, Texas, USA (C. Kralicek)

Main Article

Table

Descriptive statistics of HAV infection and immune response in plasma donors, United States*

Parameter No. samples Mean SD Median Range
Time to peak RNA, d† 9 12.2 3.8 11.0 8–19
Peak RNA titer, IU/mL 9 7.77 × 107 1.12 × 108 2.61 × 107 1.2 × 104‒3.1 × 108
Duration of viremia ≥100 IU/mL, d 9 54.8 23.4 55.0 14–88
Duration of detectable viremia, d 9 95.0 33.2 106.0 32–128
HAV doubling time, hours 8 18.0 3.5 17.5 14.1–24.7
Time to first positive IgM result, d† 9 21.1 10.3 19.0 7–37
Time to peak IgM S/CO ratio, d† 9 26.4 10.2 29.0 9–38
Peak IgM signal, S/CO 9 7.6 3.6 7.3 1.4‒14.4
Duration of consecutive positive IgM, d 9 36.1 19.6 42.0 1–59
Days between first and last positive IgM result 9 61.3 37.6 58.0 7–112
Time to first positive IgG result, d† 9 25.2 10.7 29.0 9–37
Plateau IgG signal, S/CO 9 10.0 2.2 10.4 5.7–13.5
Time to peak ALT, d† 8 22.0 10.5 21.0 7–37
Maximum fold-change relative to baseline ALT 8 65.1 65.4 27.0 8–159
Peak ALT titer, IU/L 8 452.1 443.4 270.5 40–1,262
No. donations analyzed/donor 9 28.6 6.4 28.0 19–41

*Parameters listed were extracted based on donors who seroconverted (n = 9); donor F was excluded because of absence of seroconversion. For 4 cases, 1 additional donor was excluded from the analysis: donor B for ALT-related parameters (no visible ALT peak) and donor E for extrapolation of HAV doubling time (no early HAV RNA-positive sample available). ALT, alanine aminotransferase; HAV, hepatitis A virus; S/CO, signal-to-cutoff ratio. †Relative to day 0 (defined as collection date with first detectable HAV RNA).

Main Article

Page created: August 02, 2021
Page updated: October 19, 2021
Page reviewed: October 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external